Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock rose 7% Monday following positive Phase 2 trial results for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), a ...

) has been revised to $7.14 / share. This is an increase of 10.53% from the prior estimate of $6.46 dated December 3, 2025. The price target is an average of many targets provided by analysts. The ...

Want to know how the Hogwarts Legacy sorting hat works? The sorting process is one of the most important factors as you start your new life at the Wizarding School of Witchcraft and Wizardry. Fans of ...

These robots are sorting out packages faster than you can say delivery. A video showing an army of tiny little yellow robots sorting out packages in a Chinese factory is the latest example of how ...